US-listed pharmaceuticals company Merck to spin off Organon after acquisition

Organon, a women’s healthcare-focused drugs developer about to be spun off from US-listed pharmaceuticals company Merck, has agreed to acquire Alydia Health for up to $240m. Organon will pay $215m upfront plus a $25m contingent milestone payment. Fifty million dollars of the upfront payment will be paid prior to the spinoff of Organon expected in…

The rest of this content is only accessible to Corporate Venturing: News, Data, and Events - Global Corporate Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.